- Zhifei Biological reported a net income of 2.23 billion yuan for the first half of 2024.
- The company generated a total revenue of 18.26 billion yuan during this period.
- Market analysts are generally positive about Zhifei Biological:
- 27 analysts recommend buying the stock.
- 2 analysts suggest holding the stock.
- None of the analysts advise selling the stock.
A look at Chongqing Zhifei Biological Products Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using Smartkarma Smart Scores have assigned Chongqing Zhifei Biological Products a positive long-term outlook based on its overall ratings. The company’s strong performance in growth, resilience, and value categories indicates promising prospects for investors. Chongqing Zhifei Biological Products focuses on researching, manufacturing, and selling vaccines and various biological products, positioning itself well in the healthcare sector.
Although the company shows slight weakness in momentum, its solid scores in other key areas suggest a stable and growing business. With a focus on innovation and product diversification, Chongqing Zhifei Biological Products is positioned to capitalize on opportunities in the market. Investors may find the company’s balanced ratings across different factors appealing for long-term investment.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
